Spectrum of Aspergillus disease and its frequency worldwide

David W. Denning

Author address: 

Professor of Medicine and Medical Mycology, Director of the National Aspergillosis Centre, The University of Manchester, UK Email: [email protected]; Web www.life-worldwide.org


The genus Aspergillus, and its associated diseases, is extraordinary and unparalleled by any other microorganism. The spectrum of aspergillosis extends from allergy in the nose and sinuses (allergic Aspergillus rhinosinusitis) to the lungs (manifesting in subtly different ways) (allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS)), to slowly progressive pulmonary or sinus destruction in apparently normal individuals (and other mammals and birds) (chronic pulmonary aspergillosis and granulomatous Aspergillus rhinosinusitis) and to immediately life-threatening invasive infection in immunocompromised patients (invasive aspergillosis). Globally, there are estimated to be 4.8 million with ABPA complicating asthma in adults (193 million), 6–15 million with SAFS, 1.2 million patients with chronic pulmonary aspergillosis following pulmonary tuberculosis (30-80% of the total CPA caseload, estimated at 3 million) and over 200,000 annually with invasive aspergillosis. There is a substantial need for new antifungal agents for aspergillosis, especially oral drugs. A. terreus and A. nidulans are intrinsically resistant to amphotericin B. Acquired resistance to triazoles in A. fumigatus is increasing. The genomic variation in the Aspergillus genus is remarkable and testament to its adaptability; A. fumigatus and A. nidulans are as distantly related as fish and man representing huge evolutionary changes in ~200 million years. Key links: www.LIFE-Worldwide.org and www.fungalinfectiontrust.org/fungaldis.html


abstract No: 


Full conference title: 

Microbiology Society Annual Conference
    • MS 2013